Musitox® Project: Consumption of Psychoactive Substances at Music Festivals in Aquitaine (NCT03203213) | Clinical Trial Compass
CompletedNot Applicable
Musitox® Project: Consumption of Psychoactive Substances at Music Festivals in Aquitaine
France25 participantsStarted 2017-06-30
Plain-language summary
Poisoning by psychoactive substances is increasingly common in Europe and can be responsible for deaths. These substances, also called "festive drugs", circulate among other places in festive gatherings (night clubs, concerts, free music, feria, etc.). The main objective of this study is to determine the molecules that circulate in festive events in Aquitaine, in order to implement prevention actions by looking at whether the circulating substances vary with the style of event.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Any patient admitted to the Emergency Medical Post with neurological and / or behavioral disorders:
* agitated at the time of admission to the PMA or during surveillance at the LDC
* and who will say (or for whom his entourage will say that he has) consumed psychoactive substances
* or who will be unable to say that they have taken a psychoactive substance and for which no other etiology is evident
* and / or for which the seriousness of the case necessitates admission to the emergency or intensive care, whether or not the physician is aware of a psychoactive substance (and in the absence of an obvious etiology)
* and / or if the PMA physician considers that analytical research is needed for further care
* Oral Express Consent
* any patient who is in possession of an identity document proving his / her majority (over 18 years).
Exclusion Criteria:
* Refusal of the patient to take a sample, or to participate in the study
* Minors (under 18 years of age)
* Pregnant women
* Breastfeeding women
* Patient who can not prove his / her age by the production of an identity document.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Number of patients who have consumed new psychoactive substances